Nektar Therapeutics
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
Current Price
$70.62
-4.99%Profile
Valuation (TTM)
Market Cap$2.03B
P/E-12.81
EV—
P/B22.55
Shares Out28.69M
P/Sales36.42
Revenue$55.63M
EV/EBITDA—
Nektar Therapeutics (NKTR) Stock Analysis
Market Cap$2.03B
Current Price$70.62
P/E Ratio-12.81
Forward P/E—
PEG Ratio0.26
EPS$-9.73
Book Value$3.13
P/B Ratio22.55
NKTR Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Debt: 71M
Revenue
115M
FY19
153M
FY20
102M
FY21
92M
FY22
90M
FY23
98M
FY24
55M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
NKTR 52-Week Range
$8.51
$100.35
50-Day MA: $78.80200-Day MA: $56.55
Did you know?
Price sits at 68% of its 52-week range.
Nektar Therapeutics (NKTR) Financial Summary
Nektar Therapeutics (NKTR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $70.62 with a market capitalization of $2.03B.
Key valuation metrics include a P/E ratio of -12.81, price-to-book ratio of 22.55, and EPS of $-9.73. The company reports a profit margin of -284.2% and return on equity of -176.0%.
NKTR Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $2.03B |
| P/E Ratio | -12.81 |
| EPS | $-9.73 |
| P/B Ratio | 22.55 |
| P/S Ratio | 36.42 |
| Profit Margin | -284.2% |
| Return on Equity | -176.0% |
| Debt/Equity | 0.95 |
NKTR Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $114.62M | $-440.67M |
| FY20 | $152.91M | $-444.44M |
| FY21 | $101.91M | $-523.84M |
| FY22 | $92.06M | $-368.20M |
| FY23 | $90.12M | $-276.06M |
| FY24 | $98.43M | $-118.96M |
| FY25 | $55.23M | $-164.08M |
NKTR Quality Indicators
Nektar Therapeutics maintains a profit margin of -284.2% and an operating margin of -253.7%. Return on equity stands at -176.0%. The current ratio is 4.97. Debt-to-equity ratio is 0.95.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
NKTR Free Cash Flow
Nektar Therapeutics generated $-209.38M in trailing twelve-month free cash flow, representing an FCF yield of -10.33%. This low FCF yield may reflect heavy reinvestment or growth spending.
NKTR Shares Outstanding
Nektar Therapeutics has 0.03 billion shares outstanding at a share price of $70.62, giving it a market capitalization of $2.03B.